Unraveling a Therapeutic Conundrum: A Town Hall on Barriers to Access PCSK9 Inhibitors
Overcoming barriers to access PCSK9 Inhibitors
As new options for the treatment of disease become available, a protocol arises that is based on the FDA indications and national guidelines. In the case of atherosclerotic cardiovascular disease, patients are being denied coverage for the majority of prescriptions written for PCSK9 inhibitors despite meeting the indications.
Board of Directors, American Society for Preventive Cardiology
Sponsored by ASPC with support from Amgen and Sanofi Regeneron